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We have previously reported that casein hydrolysate, CH-3, from bovine milk and
casein-derived tripeptide Met-Lys-Pro (MKP) has ACE inhibitory activity and reduces
blood pressure. In this study, we investigated the therapeutic effects of MKP in a
hypertensive rat model (7-week-old male SHRSP/Izm rats). For long term evaluation,
rats were fed either a diet containing CH-3 or normal diet. The survival rate of SHRSP
rats was significantly improved by intake of CH-3 for 181 days. For short term evaluation,
rats were orally administered synthetic tripeptide MKP or distilled water for 4 weeks.
MRI study demonstrated that hemorrhagic lesions were observed in two of five rats
in the control group, while no hemorrhagic lesions were observed in the MKP group.
Volumetric analysis using MRI revealed that MKP administration inhibited atrophy of
diencephalic regions. Histological examinations revealed that hemorrhage areas and
astrogliosis in the hippocampus and cerebral cortex were lower in the MKP group
than in the control group. Gene expression analysis indicated that MKP administration
reduced expression of genes related to cerebral circulation insufficiency such as immune
responses (Cd74 and Prkcd), response to hypoxia (Ddit4, Apold1, and Prkcd), reactive
oxygen species metabolic process (Ddit4 and Pdk4), and apoptotic process (Ddit4,
Prkcd, and Sgk1), suggesting that MKP administration prevented cerebral ischemia
associated with hypertension. In addition, some genes encoding responses to hormone
stimulus (Fos, Dusp1, and Sik1) were also downregulated. Serum aldosterone and
corticosterone levels were also significantly decreased following MKP administration.
The present study indicates that MKP shows neuroprotective effects in SHRSP rats by
regulating cerebral circulation insufficiency and corticoid levels. MKP administration may
therefore be a potential therapeutic strategy for hypertensive brain diseases such as
cerebrovascular disease.
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INTRODUCTION
Hypertension is a major risk factor for cerebrovascular disorders such as stroke, vascular
dementia, transient ischemic attacks, and subarachnoid hemorrhage. Elevated blood pressure (BP)
induces arteriosclerosis in cerebral and peripheral blood vessels, and arteriosclerosis leads to a
wide variety of diseases including ischemia, bleeding, and infarction (Fisher, 1965) as well as
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dementia (Walker et al., 2019). The incidence of stroke increases
in proportion to both systolic and diastolic blood pressure, with
a relative risk increase of 3.1 times in men and 2.9 times in
women (Kannel et al., 1970, 1981). Hypertension is also known
to exacerbate stroke outcomes. Although hypotension is also
detrimental to stroke, hypertensive patients have larger infarcts
and less peripheral tissue which can be rescued compared to
normotensive patients (Leonardi-Bee et al., 2002; Ahmed et al.,
2009). In addition, hypertension has been reported to be a major
risk factor for cerebral small vessel disease (CSVD), which causes
lacunar stroke and cognitive decline (Veglio et al., 2009). Several
studies using a hypertensive model reported that vascular injury
in the large and small blood vessels of the brain markedly reduced
cerebral circulation and is involved in the exacerbation of stroke
(Strandgaard, 1978; Muller et al., 2012). Circulatory failure in
the brain occurs after inward remodeling in the aorta and small
arteries, reducing the vascular lumen diameter and vasodilator
reserve. It has been reported that ischemic damage due to cerebral
circulatory failure may cause disruption of nerve activation,
alteration of vasoactive metabolites, and vascular dysfunction
(Faraci and Heistad, 1990). Thus, the influence of hypertension
on cerebral circulation is considered important in the process of
cerebrovascular disease.
Cerebral ischemia induces various pathological conditions in
the brain such as hypoxia, oxidative stress, and inflammation.
These pathological changes cause damage to neurons, glia, and
vascular cells in the neurovascular unit as well as breakdown
of the blood-brain barrier (BBB) through disengagement of
tight junctions (Ohmori et al., 2018). Increased reactive oxygen
species (ROS) induced extracellular matrix denaturation via
matrix metalloproteinase (Rempe et al., 2016), and enhanced
DNA damage that led to cell damage and apoptosis (Chan,
2001). ROS and fatty acid peroxides are also increased in
neurodegenerative diseases, including AD, Parkinson’s disease,
and amyotrophic lateral sclerosis. These findings suggest that
oxidative stress impairs cellular functions and contributes to an
exacerbation of neuropathology (Barnham et al., 2004; Singh
et al., 2019). Wang and Xu (2020) reported that brain damage
was suppressed by treatment with antioxidants such as curcumin.
Since ischemic stress associated with arteriosclerosis triggers ROS
production in cases of hypertension, antihypertensive agents
such as angiotensin-converting enzyme (ACE) inhibitors and
angiotensin II type 1 receptor blockers (ARBs) may be useful for
early intervention.
The renin angiotensin system (RAS) is a hormone system
within the body that is essential for the regulation of blood
pressure and fluid balance. Angiotensin II is an important
hormone of the RAS that causes endothelial dysfunction and
has been shown to increase cerebral artery tone through its
interaction with the angiotensin receptor 1 (AT1R) (Saavedra
and Nishimura, 1999; Griendling et al., 2000; Dzau, 2001;
Nickenig and Harrison, 2002). In addition, angiotensin II
activated the NADPH-oxidase complex via AT1R and induced
oxidative stress and inflammation (Labandeira-Garcia et al.,
2017). It was recently reported that the RAS existed not only
systemically, but also locally in organs such as the kidney and
brain (Hosomi et al., 2013; Sansoè et al., 2020). Regulation of
the RAS by ACE inhibitors and ARBs has been reported to
improve stroke outcome in hypertensive animals and reduce
the severity of ischemic stroke in humans (Werner et al., 1991;
Walther et al., 2002; Iwai et al., 2004; Hosomi et al., 2005;
Chitravas et al., 2007; Nagai et al., 2011; Panahpour et al.,
2014). Several studies reported that regulation of the RAS
by ACE inhibitors and ARBs has a cerebral protective effect
against ischemic stroke independent of a hypotensive effect,
whereas non-RAS antihypertensive agents such as hydralazine
and nimodipine have not shown cerebral protection (Hosomi
et al., 2005; Kozak et al., 2008; Omura-Matsuoka et al., 2009;
Smeda and Daneshtalab, 2011; Smeda et al., 2018). Interestingly,
these findings suggest that the beneficial effects of intervention
to the renin-angiotensin system on ischemic stroke are not
necessarily due to its antihypertensive effects. Furthermore, it has
been reported that administration of ACE inhibitor captopril in
Stroke-Prone Spontaneously Hypertensive Rat (SHRSP) exerted
a tissue protective effect against stroke and created severe vascular
lesions independently of the blood pressure lowering (Stier et al.,
1991). Ohta et al. (1995) showed that the occurrence of vascular
lesions and vascular necrosis were significantly suppressed in
various organs, including the brain, in SHRSP rats treated with
drugs (ACE inhibitor and calcium channel blockers), in doses
which did not show antihypertensive effects, and blood pressure
exceeded 250 mmHg for a long time. Although there was no
difference in antihypertensive effects comparing ACE inhibitor
and calcium channel blockers, inhibition of vascular smooth
muscle cell proliferation was superior with ACE inhibitor.
Regulation of RAS has been shown to reduce stroke-induced
Ang II and matrix metalloproteinase activation, and one
mechanism by which regulation of RAS improves outcome is
to prevent edema formation and hemorrhagic transformation.
It is suggested that these effects are due to suppression of
degeneration of vascular smooth muscle cells (Ohta et al., 1995;
Hosomi et al., 2005). Namely, the beneficial effects elicited
by RAS modulation on stroke outcome is multifactorial. RAS
modulation is highly useful because it can be expected to have
complex physiological activities in addition to its known action
via hypotension.
A number of studies have reported that food-derived
components have antihypertensive effects. For example,
food-derived peptides from milk (Ile-Pro-Pro and Val-Pro-Pro)
and sardine peptides exert hypotensive effects via ACE inhibitory
activity (Matsui et al., 1993; Nakamura et al., 1995). We also
demonstrated that 5 mg/kg to 100 mg/kg of casein hydrolysate
CH-3 has hypotensive effects in spontaneously hypertensive
rats (SHRs) (Yamada et al., 2013). The functional component
of CH-3 is Met-Lys-Pro (MKP), which is an αS2 casein-derived
tripeptide with high ACE inhibitory activity (Yamada et al.,
2013). Oral ingestion of 0.5 mg/kg to 1.0 mg/kg of MKP showed
hypotensive effects for both single and multiple administrations
in SHRs (Yamada et al., 2015). Our recent evidences have shown
that MKP-containing peptides lowered systolic blood pressure
in a clinical trial in subjects with high blood pressure (Yuda
et al., 2018). However, these evaluation systems are relatively
mild hypertensive models, and a model of severe hypertension
has not yet been verified. In addition, animal studies suggested
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that MKP-containing peptides improved cognitive function and
cerebral blood flow in an AD mouse model treated by amyloid
β intracerebroventricular administration (Min et al., 2017).
250 mg/kg of CH-3 and 0.5 mg/kg of MKP reduced cognitive
decline in this study. Further, autoradiography indicated that
14C-labeled MKP, Met-[1-14C]-Lys-Pro, was distributed in the
brain, suggesting that MKP can cross the BBB to exert its effects
(Min et al., 2017). However, the precise mechanism remains
unknown. In this study, therefore, we explore the mechanisms
underpinning the neuroprotective effects of MKP in a severe
hypertensive model, SHRSP/Izm rats. This animal model shows
extremely high blood pressure from young adulthood and easily
develops cerebrovascular disorders, and has been widely used
for evaluating cerebral vascular disorders and brain damage
(Braun et al., 2012). Therefore, we used this model to conduct
morphological and molecular biological evaluation to verify the
brain protective effects of MKP.
The aim of this study is to clarify whether neuropathy in a
severe hypertensive model is improved by MKP. This research is
significant because elucidation of the function of MKP is expected
to contribute to the prevention of cerebrovascular and related
diseases associated with hypertension.
MATERIALS AND METHODS
Animals
Male SHRSP/Izm at 6 weeks of age were used in the present
study (Japan SLC, Hamamatsu, Japan). The rats were maintained
in standard laboratory cages with free access to food and water
throughout the study period under a 12 h light/dark cycle. The
animals were acclimated for 1 week prior to the experiments
and administration started at 7 weeks of age. CH-3 was prepared
by Morinaga Milk Industry Co., Ltd. As described previously
(Yamada et al., 2013), MKP content of CH-3 is 0.045%. MKP was
prepared by solid-synthesis by Peptide Institute, Inc. (Ibaraki,
Japan). All animal experimental procedures in this study were
approved by the Committee on Animal Care and Use of Shiga
University of Medical Science (Protocol #19-082 and #19-083)
and the Institutional Animal Care and Use Committee of
Morinaga Milk Industry Co., Ltd. (#16-043 and #18-071). The
experimental period was from February 2017 to July 2019.
First, we conducted a study using CH-3 to observe whether
food materials containing MKP are effective. To test the effects of
CH-3 on survival rates in SHRSP/Izm rats, 20 rats were divided
into two groups: 10 rats received a regular diet (SP diet; Funabashi
Farm, Funabashi, Japan), and the other 10 rats received SP diet
containing 0.1% CH-3. The supplementation was performed
on 7-week-old rats. All animals were carefully monitored for
6 months. The average CH-3 intake during the administration
period was 89 mg/kg.
To investigate the effects of MKP, the functional component
of CH-3, on SHRSP/Izm rats, 20 rats were divided into two
groups. Each group consisted of 10 rats that received MKP
(0.5 mg/kg/day) or the vehicle (saline), once a day for 4 weeks
by oral administration. The dose of MKP was determined
with reference to previous studies (Yamada et al., 2015;
Min et al., 2017). The rats were perfused through the aorta
with 10 mM phosphate-buffered saline (pH 7.4; PBS) at 11 weeks
of age under deep anesthesia with sevoflurane, and brains were
quickly removed. Five of ten brains in each group were fixed
with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH
7.4; PB) for 24 h at 4◦C, and then transferred to 15% sucrose
in 0.1 M PB containing 0.1% sodium azide. The fixed brains
were subjected to magnetic resonance imaging (MRI). The five
remaining brains in each group were cut into two hemispheres
in the sagittal plane. Half of the brain hemispheres were snap
frozen and subjected to RNA extraction. The other half were
immersed in 4% PFA in 0.1 M PB for 24 h at 4◦C followed by
15% sucrose in 0.1 M PB containing 0.1% sodium azide for
immunohistochemistry.
Histological Analysis
Immunohistochemical analysis was performed as previously
described (Yanagisawa et al., 2015; Ibrahim et al., 2017).
Briefly, free-floating sagittal brain sections were washed with
0.1 M PBS containing 0.3% Triton X-100 (PBS-T, pH 7.4)
and then incubated in 0.3% hydrogen peroxide in PBS-T for
20 min at room temperature (RT) to eliminate endogenous
peroxidase activity. After three 10-min washes in PBS-T,
the sections were blocked with 2% bovine serum albumin
(BSA) in PBS-T for 30 min at RT. Blocked sections were
then incubated with rabbit polyclonal anti-GFAP antibody
(1:5,000; Dako, Glostrup, Denmark) in PBS-T containing 0.2%
BSA overnight at 4◦C. After several washes with PBS-T,
immunolabeled sections were incubated with biotinylated
goat polyclonal anti-rabbit IgG antibody (1:1,000; Vector
Laboratories, Burlingame, CA, United States) for 60 min at RT.
Following several washes with PBS-T, sections were incubated
with avidin-biotin complex solution (Vectastain ABC Elite kit,
1:3,000; Vector Laboratories) for 60 min at RT, and washed
several times with PBS-T. Immunolabeling was visualized
with 3,3′-diaminobenzidine (Dojindo Laboratories, Kumamoto,
Japan) with nickel ammonium sulfate. Images were captured with
a camera (DP27, Olympus). GFAP-positive areas were measured
with NIH ImageJ software. Images were transformed to eight-bit
grayscale. Threshold was set to 120 for hippocampus and 170 for
cortex and percent of pixel intensity was quantified. The value of
GFAP-positive area in each animal was calculated by averaging
the values from three sections collected every ten sections.
Magnetic Resonance Imaging
Ex vivo MR data of fixed brains were acquired with a 7.0 T Unity
Inova System (Agilent, Santa Clara, United States) (Amatsubo
et al., 2009; Yanagisawa et al., 2011, 2014). A custom-made
volume coil with a 3.5-cm inner diameter was used to collect
the data. The MR images of rat brains were obtained with
T2-weighted 3D fast spin echo sequence; 4,000-ms repetition
time (TR), 20-ms effective echo time (TEeff), four echo train
length with 10-ms echo spacing, a 24 mm× 24 mm× 16 mm field
of view (FOV), and 256× 128× 96 acquisition matrices. The size
of the acquisition pixel was 0.094 mm × 0.188 mm × 0.167 mm
(2.93 nL). The total scan time of one data set was 3 h 24 min
56 sec. The acquired data were finally processed into a 3D image
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of 256 × 256 × 128 pixels using 3D Fourier transformation.
Segmentation of gray matter (GM) and white matter (WM)
was performed using tissue probability maps (TPMs). The
voxel size was calculated with SPM software (Wellcome Trust
Center for Neuroimaging, UCL Institute of Neurology, London,
United Kingdom) (Hikishima et al., 2017). The rat label atlas
was transformed into the brain morphology of each individual
using advanced normalization tools (ANTs) software (Valdés-
Hernández et al., 2011). The volume of the tissue segmentation
was measured. To identify cerebral hemorrhage, itk-snap was
used. The hemorrhage sites were defined as a region showing a
clear low signal close to regions with a faint high signal intensity
due to inflammation or edema on T2WI.
Microarray Analysis
Total RNA in hippocampus was isolated using RNeasy Plus
Universal Kit (Hilden, Germany) according to manufacturer’s
instructions. RNA integrity, quality, and quantity were evaluated
with microcapillary electrophoresis (2100 Bioanalyzer, Agilent
Technologies, Santa Clara, CA, United States) using the RNA
6000 Nano kit. Only samples with an RNA integrity number
(RIN) of greater than eight were used for further analysis. RNA
samples (three from each group) were used for microarray
experiment with SurePrint G3 Rat Gene Expression v2 8 × 60 K
Microarrays according to the manufacturer’s instructions
(Agilent Technologies, United States). The normalization and
expression analysis of the microarray data were performed
with GeneSpring GX software (v13.1, Agilent Technologies,
United States). Normalized expression results were summarized
as log2 transformed values for each transcript. Statistical
analysis was performed with the linear analysis of microarray
technique from “limma” package (Ritchie et al., 2015). Genes
with significant changes in transcript abundance were selected
based on two criteria: a p-value of less than 0.05 and a cutoff in
transcript abundance of at least two-fold.
RNA Preparation and Quantification of
Gene Expression
Total RNA from animal tissue was isolated using RNeasy
Plus Universal Kit according to the manufacturer’s protocol.
The RNA concentration was determined spectrophotometrically,
and cDNA was synthesized using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City,
United States). cDNA was amplified by real-time PCR with an
Applied Biosystems 7500/7500 Fast Real-Time PCR System using
SYBR Green fluorescence signals. Normalization for loading was
accomplished by assessing Gapdh. The primer sets for target
genes are shown in Table 1.
LC-ESI-MS/MS for Serum Corticoid
Measurement
Samples were prepared as described below to measure
aldosterone (Ald) and corticosterone (B). As internal standards,
aldosterone-d7 (Ald-d7) and corticosterone-d4 (B-d4) were
added to the rat serum, which was diluted with 1 mL of distilled
water. Steroids were then extracted by 4 mL of t-butyl methyl
ether. After the organic layer was evaporated to dryness, the
extract was dissolved in 0.5 mL of methanol and diluted with
1 mL of distilled water. The sample was applied to an Oasis MAX
cartridge, which had been successively conditioned with 3 mL of
methanol and 3 mL of distilled water. The cartridge was washed
with 1 mL of 1% acetic acid and 1 mL of methanol/distilled
water mixture (45:55, v/v) successively. The steroids were then
eluted with 1 mL of methanol. After the eluted fraction was
evaporated to dryness, the residue was reacted with 0.25 mL
TABLE 1 | The primers used in this study.
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of hydrochloric acid/ethanol mixture (1:5, v/v) for 30 min at
RT. The reaction mixture was neutralized with 1 mL of 5%
sodium hydrogen carbonate solution and extracted with 4 mL of
t-butyl methyl ether. After the organic layer was evaporated to
dryness, the residue was reacted with 50 µL of the derivatization
mixture (80 mg of 2-methyl-6-nitrobenzoic anhydride, 20 mg
of 4-dimethylaminopyridine, and 40 mg of picolinic acid in
1 mL of acetonitrile) and 10 µL of triethylamine for 30 min at
RT. After the reaction, the sample was diluted with 0.5 mL of
ethyl acetate/hexane/acetic acid mixture (15:35:1, v/v/v), and
the sample was applied to an InertSep SI cartridge, which had
been successively conditioned with 3 mL of acetone and 3 mL
of hexane. The cartridge was washed with 1 mL of hexane and
2 mL of ethyl acetate/hexane mixture (3:7, v/v). The derivatized
steroids were then eluted with 2.5 mL of acetone/hexane mixture
(7:3, v/v). After evaporation, the residue was dissolved in 0.1 mL
of acetonitrile/distilled water mixture (2:3, v/v), and 20 µL of
the solution was subjected to the Liquid Chromatograph – Mass
Spectrometry (LC-MS/MS) instrument.
For measuring Ald and B in rat serum, an API-4000 triple
stage quadrupole mass spectrometer (Sciex, Mass, United States)
connected to LC-30AD, RACKCHANGER II (Shimadzu,
Kyoto, Japan), ESI ion source device was employed. The
column was a Kinetex C18 (150 mm × 2.1 mm, 1.7 µm,
Phenomenex, CA, United States) used at 50◦C. The mobile
phase consisting of acetonitrile and 0.1% formic acid was
used with a gradient elution at a flow rate of 0.5 mL/min.
Ion spray voltage (IS), Collision Activated Dissociation
(CAD), Curtain Gas (CUR), and ion source temperature
(TEM) parameters were 5,500 V, 4 psi, 15 psi, and 350◦C,
respectively. The SRM transitions of Ald, Ald-d7, B, and
B-d4 were m/z 494.2/448.3, 501.2/455.2, 452.3/311.3, and
456.3/315.3, respectively.
Statistical Analysis
Differences between treatment groups were analyzed using
SPSS 25.0 for Windows (SPSS Inc., Chicago, IL, United States).
Data are expressed as mean ± SEM. A p-value of <0.05 was
considered statistically significant. Student’s unpaired t-test
or Mann-Whitney U-test were used for between-group
comparisons. Survival rates were examined using the
Kaplan-Meier method and compared using a log-rank test.
Statistical analysis for microarrays is described in “Microarray
Analysis” section.
RESULTS
CH-3 Prolongs Life Span in SHRSP/Izm
Rats
To explore the effects of casein hydrolysate (CH-3) on life span,
SHRSP/Izm rats were fed a SP diet with or without CH-3 for
181 days. Compared using the log-rank test, the survival rate
was significantly improved in the CH-3 group (p < 0.05). In
the control group, the mean life span was 85 ± 8 d during
the experimental period. Mean life span was prolonged in the
CH-3-treated group (125 ± 16 d). The CH-3 treatment resulted
in a reduction of total mortality by 40% at the end of the
experimental period (Figure 1).
General Characteristics of Animals
To determine the brain protective effects of tripeptide MKP,
rats were administrated MKP for 4 weeks. Body weight and
blood pressure were measured during the experimental period.
After sacrifice, brains were excised and analyzed. There were
no significant differences between groups in body weight, brain
weight, blood pressure, and changes of blood pressure from
baseline (Tables 2, 3). Changes in systolic blood pressure
(SBP) over 4 weeks in the control and MKP groups were
65.7 ± 6.3 mmHg and 55.7 ± 4.8 mmHg, respectively. Changes
in blood pressure showed a trend to be smaller in the MKP
group but this did not reach significance. Hemorrhagic lesions
in the brains were observed by ex vivo MR imaging in T2WI.
In the MKP group, hemorrhagic lesions were not observed.
In contrast, hemorrhagic lesions were observed in two of five
FIGURE 1 | Survival rate of SHRSP/Izm rats up to 181 days. Survival curves
were generated using Kaplan-Meier methods. Data were analyzed by log-rank
test to compare groups. n = 10 per group.
TABLE 2 | Body and brain weights in SHRSP rats.
Body weight (g) Brain (g) Brain (g/kg BW)
Control 257.87 ± 6.54 1.95 ± 0.02 7.59 ± 0.21
MKP 263.70 ± 3.23 1.95 ± 0.01 7.41 ± 0.09
Values are presented as mean ± SEM. n = 9 in each group.
TABLE 3 | Changes in blood pressure from baseline in SHRSP rats.
SBP (mmHg) DBP (mmHg)
2w 4w 2w 4w
Control 41.3 ± 3.9 65.7 ± 6.3 30.1 ± 6.0 53.3 ± 7.4
MKP 35.4 ± 2.8 55.7 ± 4.8 34.0 ± 10.4 48.4 ± 7.3
Values are presented as mean ± SEM. n = 9 in each group.
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rats in the control group (Figure 2, arrows). The volume of
each hemorrhagic lesion was 11.13, 0.08, 0.07, and 0.04 mm3 for
lesions a–d, respectively.
Immunohistochemical Staining of Brain
Astrocytes
Immunohistochemical staining for GFAP was performed to
evaluate astrocyte activation in brain sections of SHRSP rats.
Representative immunohistochemical staining for GFAP in the
hippocampus and cerebral cortex are shown in Figures 3, 4,
respectively. In the hippocampus, GFAP-positive areas in the
control and MKP groups were 30.9 ± 2.0 and 18.9 ± 2.0%,
respectively (Figure 3C). In the cerebral cortex, GFAP-positive
areas in the control and MKP groups were 18.1 ± 0.9 and
11.6 ± 0.6%, respectively (Figure 4C). The MKP-treated group
exhibited significantly lower GFAP-immunoreactivity in both the
hippocampus and cerebral cortex compared to that in control rats
(p< 0.05), suggesting that administration of MKP suppressed the
activation of astrocytes in the SHRSP rat brain.
Volumetric Analysis of Brain MRI
To evaluate brain morphological changes, volumetric analyses
by MRI were performed. The total brain volume in control and
MKP groups was 1751.4 ± 22.3 mm3 and 1774.9 ± 28.6 mm3,
respectively. Next, we evaluated GM and WM volume. There was
no difference in WM and GM volume between groups based
on TPMs (Figures 5A,B and Table 4). Next, we conducted
brain segmentation using a rat label atlas to evaluate the
FIGURE 2 | T2WI coronal MRI. The images of MRI slices in the rat indicate hemorrhage legions. Two individuals in the control group with lesions are shown in (A)
and (B), respectively. Cerebral hemorrhage (a–d) are depicted as regions showing a clear low signal near regions with a faint high signal intensity of inflammation or
edema on T2WI. a–d show different lesion, respectively.
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FIGURE 3 | Expression of GFAP in the hippocampus. Immunohistochemistry images of control (A) and MKP (B) are shown. Percentage of immunoreactive area in
each group is represented in (C). Values are presented as mean ± SEM. Data were analyzed by Student’s t-test. *p < 0.05 compared to control group (Control:
n = 4, MKP: n = 5).
volume of a small region (Figure 5C). The volume of
hippocampus and amygdala was not significantly different
between groups. However, intergroup differences in volume
changes were observed in the diencephalic region (p < 0.05).
In the left hemisphere, the volume of the diencephalon
(Control: 47.5 ± 0.6 mm3, MKP: 50.2 ± 0.5 mm3), pituitary
(Control: 2.0 ± 0.1 mm3, MKP: 2.4 ± 0.1 mm3), and
pallidum (Control: 7.8 ± 0.1 mm3, MKP: 8.2 ± 0.1 mm3)
were significantly increased following MKP administration. The
volume of the hypothalamus in the left (Control: 17.5± 0.3 mm3,
MKP: 19.1 ± 0.5 mm3) and right hemispheres (Control:
17.9 ± 0.2 mm3, MKP: 19.5 ± 0.6 mm3) showed an increasing
trend with MKP administration. However, statistical significance
could not be claimed (Table 4).
Hippocampus Transcriptomic Signature
in SHRSP Rats
To identify early changes in hippocampal gene expression
following MKP treatment in SHRSP rats, transcriptional profiles
of hippocampal tissue treated with MKP were compared to
control tissue by microarray. No genes were significantly
upregulated by MKP administration compared to control.
Conversely, Ddit4, Cel, Nfkbia, Pdk4, Cd101, Fos, Depp1 Cd74,
Sgk1, Thbs2, Apold1, S100a11, Sik1, Aspa, Dusp1, Col6a3, Wdr38,
and Prkcd were 0.5-fold downregulated compared to control
levels (Figure 6A). Gene Ontology (GO) term enrichment
analyses were performed on the 18 downregulated genes in
the MKP treatment group with DAVID 6.8. We identified
11 significant gene terms in GO biological processes, four
terms in GO cellular components, and four terms in GO
molecular function (Figure 6B). Of note, identified genes were
related to cerebral circulation insufficiency such as immune
responses (Cd74 and Prkcd), response to hypoxia (Ddit4, Apold1,
and Prkcd), reactive oxygen species metabolic process (Ddit4
and Pdk4) and apoptotic process (Ddit4, Prkcd, and Sgk1),
suggesting that MKP administration prevented cerebral ischemia
associated with hypertension. In addition, some genes encoding
responses to hormone stimulus (Fos, Dusp1, and Sik1) were
also downregulated.
Validation of mRNA Expression
To confirm the expression of genes identified in microarray
analysis, total RNA from the hippocampus and cerebral cortex
was measured by RT-qPCR. Apold1, Fos, Fosl1, Sik1, Dusp1, and
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FIGURE 4 | Expression of GFAP in the cerebral cortex. Immunohistochemistry images of control (A) and MKP (B) groups are shown. Percentage of immunoreactive
area in each group is represented in (C). Values are presented as mean ± SEM. Data were analyzed by Student’s t-test. *p < 0.05 compared to control group
(Control: n = 4, MKP: n = 5).
Pdk4 were significantly downregulated by MKP administration
in the hippocampus (p < 0.05), (Figure 7A). These genes were
less than 0.65-fold decreased. Cel was 1.57-fold upregulated in the
MKP group. In the cerebral cortex, Nfkbia, Dusp1, and Pdk4 were
significantly downregulated by MKP administration (p < 0.05),
(Figure 7B). These genes were less than 0.70-fold decreased.
Fos, Dusp1, and Pdk4 encode cellular responses to hormonal
stimuli. Other downregulated genes are involved in responses to
hypoxia and ROS metabolism, indicating that oral intake of MKP
suppressed cerebral circulatory insufficiency associated with
hypertension and modulated hormonal responses in the brain.
Serum Corticoids
Based on the gene expression results, we hypothesized
that metabolic changes in corticoids had occurred, so
we measured serum mineralocorticoids (aldosterone) and
glucocorticoid (corticosterone) levels. Serum aldosterone levels
of control and MKP groups were 223.8 ± 40.4 pg/mL and
36.3 ± 10.4 pg/mL, respectively. Serum corticosterone levels
of control and MKP groups were 534.2 ± 95.6 ng/mL and
136.8 ± 50.7 ng/mL, respectively. As such, MKP administration
significantly suppressed the production of serum corticoids
(p < 0.05) (Figure 8).
DISCUSSION
A previous report showed that intake of CH-3 or MKP reduced
blood pressure in SHR rats (Yamada et al., 2013). In addition,
oral intake of MKP suppressed the elevation of blood pressure
in patients with high-normal blood pressure (Yuda et al.,
2018). However, these models are relatively mild hypertension
models, and the effects of MKP have not been examined in
models that develop severe hypertension such as SHRSP. In this
study, we first examined the survival rate using CH-3, casein
hydrolysate, which contains MKP. We also demonstrated that
the survival rate of SHRSP rats was significantly improved by
Frontiers in Neuroscience | www.frontiersin.org 8 August 2020 | Volume 14 | Article 845
fnins-14-00845 August 14, 2020 Time: 12:9 # 9
Tada et al. Cerebral Protective Effects of MKP
FIGURE 5 | Coronal slices of gray matter and white matter detected using
tissue probability maps (TPMs). MR images of gray matter (A) and white
matter (B). Horizontal slices of tissue segmentation slices are shown in (C).
The rat label atlas was transformed into the brain morphology of each
individual using ANTs. The volume of each brain region was measured.
intake of CH-3 for 181 days (Figure 1). Minami et al. (1985)
have examined the cause of death in SHRSP, and it has been
reported that all SHRSP rats die from cerebral hemorrhage
or cerebral infarction. We estimated that cerebral hemorrhage
and cerebral infarction were the causes of death in the present
study as well. Since improvement in survival rate was observed
in this experiment, the effect of MKP, which we are focusing
on as an active ingredient of CH-3, was directly examined in
following experiments. In the short-term study on MKP, the oral
administration of MKP for 4 weeks showed a trend of smaller
elevation of blood pressure in the MKP group than control
group but was not significant (Table 3). Previous studies have
reported that ACE inhibitors and ARBs administered to SHRSP
rats produced brain-protective effects, such as suppression of
cerebral hernia and hematoma expansion, without lowering
blood pressure, indicating that the antihypertensive effect is
not always required for brain-protective effects (Smeda and
Daneshtalab, 2011; Smeda et al., 2018). However, we believe that
the effect of MKP could be examined with a higher accuracy
by reviewing the experimental methods, such as the dosage,
based on the results of the present study, and we regard it as
a future issue. The MRI study demonstrated that hemorrhagic
lesions were observed in two of five rats in the control group,
TABLE 4 | Volume analysis of tissue segmentation by MRI.
Total Control MKP
Brain total volume (mm3) 1751.4 ± 22.3 1774.9 ± 28.6
Gray matter (mm3) 858.0 ± 40.4 893.7 ± 58.5
White matter (mm3) 793.4 ± 37.4 778.1 ± 21.2
Gray matter (%) 49.1 ± 2.5 50.2 ± 2.6
White matter (%) 45.3 ± 1.8 44.0 ± 1.9
Left hemisphere (mm3) Control MKP
Hippocampal formation 52.1 ± 1.8 51.0 ± 0.4
Amygdala 19.6 ± 0.6 19.5 ± 0.6
Diencephalon 47.5 ± 0.6 50.2 ± 0.5*
Hypothalamus 17.5 ± 0.3 19.1 ± 0.5
Pituitary 2.0 ± 0.1 2.4 ± 0.1*
Striatum 40.7 ± 1.1 40.7 ± 0.4
Pallidum 7.8 ± 0.1 8.2 ± 0.1*
Substantia nigra 2.2 ± 0.2 2.8 ± 0.1
Right hemisphere (mm3) Control MKP
Hippocampal formation 55.3 ± 1.5 52.8 ± 0.9
Amygdala 21.5 ± 0.8 20.4 ± 0.7
Diencephalon 46.9 ± 0.6 48.5 ± 0.5
Hypothalamus 17.9 ± 0.2 19.5 ± 0.6
Pituitary 2.0 ± 0.1 2.4 ± 0.1
Striatum 39.5 ± 0.7 41.1 ± 1.3
Pallidum 8.5 ± 0.1 8.7 ± 0.3
Substantia nigra 2.2 ± 0.2 2.3 ± 0.1
Data were analyzed by Mann-Whitney U-test. ∗p < 0.05 compared to control group
(Control: n = 5, MKP: n = 4).
while no hemorrhagic lesions were observed in MKP group
(Figure 2). In the previous study by Hayasaka et al. (2012), the
same bleeding lesion as we found in our study was evaluated in
SHRSP by various imaging methods such as contrast enhanced
CT, T2WI and H&E staining, and based on their analysis we
feel the evaluation of T2WI was appropriate. Taken together, not
only CH-3 but also MKP have the capacity to reduce cerebral
hemorrhage and prolong the lifespan.
Previously, we reported that MKP has ACE inhibitory activity
and showed hypotensive effects (Yamada et al., 2013, 2015;
Yuda et al., 2018). Therefore, we hypothesized that MKP
exerted brain protective effects via lowering blood pressure in
hypertensive model rats. However, MKP did not significantly
decrease blood pressure of SHRSP rats used in this study. As
SHRSP rats show high blood pressure values from a young
age, it is assumed that ACE inhibitory effects of MKP were
mild and did not produce statistically significant differences
in lowered blood pressure. Our results suggest that MKP may
affect the brain independently of changes in blood pressure.
The hypothesis is supported by a previous report showing that
antihypertensive drugs such as captopril inhibited hemorrhagic
expansion through non-pressure related physiological changes in
SHRSP rats (Smeda et al., 2018).
Several studies have reported that ischemia caused neuron
loss and oxidative stress in the hippocampus in a hypertensive
model (Sakurai-Yamashita et al., 2003; Solis-Gaspar et al.,
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FIGURE 6 | Microarray analysis in the hippocampus. (A) A heat map generated in MeV showing genes that were two-fold downregulated and significantly lower in
limma analysis by administration of MKP. (B) GO term enrichment analysis of the downregulated genes. The vertical coordinates are the enriched GO terms, and the
horizontal coordinates are the numbers of the downregulated genes in these GO terms. The green, purple, and orange columns represent the biological process GO
terms, cellular component GO terms, and molecular function GO terms, respectively. *p-value < 0.05. The p-values were obtained from the DAVID 2.1 method of
statistical function classification tool. n = 3 per group.
2016). To examine the underlying mechanism of cerebral
protective effects of MKP in SHRSP rats, we performed
histochemical and molecular biological analyses. Several studies
using GFAP-positive astrocytes as a marker of brain damage
demonstrated that activation of astrocytes was increased in
a mouse model of middle cerebral artery occlusion (MCAO)
or in spontaneously hypertensive rats (Tayebati et al., 2009;
Choudhury et al., 2014). The present study also showed that
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FIGURE 7 | RT-qPCR validation of expression changes of selected genes in the hippocampus and cerebral cortex in SHRSP/Izm rats. The normalized fold
expression of each gene in the hippocampus (A) and cerebral cortex (B) are represented in each bar as mean ± SEM. Data were analyzed by Student’s t-test.
*p < 0.05 compared to control group (Control: n = 4, MKP: n = 5).
astrogliosis was seen in the hippocampus and cerebral cortex
of SHRSP rats, and that activation of astrocytes in both regions
was suppressed by ingestion of MKP (Figures 3, 4). Astrocytes
are widely distributed in the mammalian central nervous system
(CNS) and play an important role in maintaining nervous
system homeostasis (Allen and Eroglu, 2017), contributing to
maintenance of brain function via immune modulation and the
BBB (Lo et al., 2003). GFAP is typically used to identify activated
astrocytes within the CNS (Eng, 1985). Astrocytic proliferation
has been reported in acute conditions such as cerebral ischemia,
as well as neurodegenerative diseases such as AD and Parkinson’s
disease (Liddelow et al., 2017). In addition, astrocytes have
been reported to be involved in lesion repair by removing
oxidative stress via the production of extracellular superoxide
dismutase and protecting neurons via endogenous ketone body
production (Puchowicz et al., 2008; Takano et al., 2013).
Therefore, astrocytic proliferation has been used as an important
pathological marker for stress. Here, our results suggest that MKP
reduced pathological changes in the brain of SHRSP rats.
The volume of the whole brain was not different between
the groups when measured by MRI as well as by tissue
weight (Tables 2, 4). Besides, MRI experiments showed that
GM and WM volumes were not different between MKP
and control groups, but volumes of specific regions were
significantly different. A preliminary evaluation of volumes
of the diencephalon such as the pituitary showed they
were increased compared to those in controls. In contrast,
there was no difference in the volume of the hippocampus and
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FIGURE 8 | Serum corticoids in SHRSP/Izm rats. The concentration of
aldosterone (A) and corticosterone (B) are represented in each bar as
mean ± SEM. Data were analyzed by Student’s t-test. *p < 0.05 compared to
control group (Control: n = 9, MKP: n = 9).
amygdala (Table 4). Sakurai-Yamashita et al. (2003) reported
that SHRSP rats with brain ischemic stress exhibited neuronal
loss with morphological changes in the hippocampus. However,
the present study did not show significant changes in the
hippocampus. Taking the case of diencephalon region, Tan et al.
(2017) reported that the hypopituitarism caused by traumatic
brain injury (TBI) was primarily caused by decreased blood
supply, and secondary damage caused by compression of the
hypothalamus-pituitary was due to oxidative stress, cerebral
edema and cerebral hemorrhage. An intracranial hypertension
model displayed increased hippocampal, hypothalamic and
pituitary apoptotic rates, but the hypothalamic and pituitary
apoptotic rates were significantly higher than hippocampus (Tan
et al., 2017). In addition, several studies have reported that
cortical infarction causes non-ischemic apoptosis in ipsilateral
thalamic and hippocampal neurons and may be associated with
post-stroke cognitive impairment (Liao et al., 2013; Chen et al.,
2017). These studies reported loss of neurons in regions such
as the thalamus is a secondary injury of infarction in the
cortex; it is possible that similar secondary injuries have occurred
in the present study where some lesions in the cortex were
observed. Furthermore, concerning the hypothalamus, a previous
study reported that BBB permeability in the hypothalamus
was significantly enhanced in SHRSP rats due to chronic
hypertension (Ueno et al., 2004). The disruption of blood vessels
is considered one of the causes of the damage to the hypothalamic
tissues in the hypertensive model. It has been suggested that MKP
may affect the volume of the diencephalic region by suppressing
such brain tissue damage. It remains unclear whether the action
is through suppression of secondary damage or of primary
damage caused by BBB disruption and blood flow decreases in the
diencephalic region. Analysis of the diencephalon region from
the viewpoint of molecular biology and pathology is regarded as
an important issue for the future.
The results of our microarray analysis of the hippocampus
indicated that MKP administration downregulated the
expression of genes related to immune responses, responses
to hypoxia, and metabolism of ROS, which are related to
cerebral vascular insufficiency due to cerebral arteriosclerosis.
Notably, some genes encoding hormonal stimuli were also
downregulated in the MKP group (Figure 6). To verify the
expression of selected genes from microarray analysis, real-time
RT-PCR analyses were performed. In the hippocampus, MKP
administration significantly decreased the gene expression
of Apold1, Fos, Fosl1, Sik1, Dusp1, and Pdk4 (Figure 7A).
In the cerebral cortex, MKP significantly decreased the gene
expression of Nfkbia, Dusp1, and Pdk4 (Figure 7B). Among
them, Fos, Dusp1, and Sik1 encode cellular responses to
hormonal stimuli. Other downregulated genes were associated
with responses to hypoxia and ROS metabolism. Therefore,
the results suggest that MKP could inhibit arteriosclerosis
and oxidative stress in the brain. Concerning genes related
to cellular responses to hormonal stimuli (Fos, Dusp1, and
Sik1), it was assumed that MKP affected the production
of corticoids such as aldosterone via ACE inhibitory
activity. Hence, we measured the concentration of serum
corticoids. Both aldosterone and corticosterone levels were
significantly decreased by MKP administration compared to
those of controls.
Corticoids regulate glutamatergic synaptic transmission in
the brain and affect learning and memory processes (Prager
and Johnson, 2009). Mineralocorticoid and glucocorticoid
overproduction induces brain nerve cell damage (Sherin and
Nemeroff, 2011; Sasaki and Yoshizaki, 2015). Moreover,
modulation of mineralocorticoid receptors (MRs) and
glucocorticoid receptors (GRs) in the brain affects cognitive
and emotional function (de Kloet et al., 2018; Wingenfeld and
Otte, 2019). Brocca et al. (2019) reported that hippocampal
damage in a hypertensive model was related to altered balance
in the activity of MR and GR. They reported that oxidative
stress caused by vascular damage and hypoxia promoted MR
activation in the hippocampus. Several studies reported that
serum aldosterone in Wistar rats was around 100 pg/mL, and
corticosterone was around 140 ng/mL(Veyrat-Durebex et al.,
2012; Svitok et al., 2014). In our study, we found that these
parameters, which were high in SHRSP rats, were suppressed
to normal levels in the MKP group. Our results revealed that
the administration of MKP reduced serum corticoid levels
(Figure 8). ACE inhibitory activity has been reported by MKP,
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and it is assumed that the effect on serum aldosterone is mediated
by the regulation of RAS. The reduction of corticosteroids may
alter expression of genes associated with MR and GR. Harvey
et al. (2017) reported that aldosterone is increased in SHRSP,
and vascular damage such as vascular fibrosis and inflammation
is induced by activation of MR-Nox1-p66Shc signaling pathway.
Reduction of vascular damage may be a factor by which MKP
reduces oxidative stress and ischemic response in brain tissue.
Since it has been indicated that cerebrovascular disease is
involved in the pathogenesis of dementia, we consider this
an important perspective to explore in future MKP research.
Further, several studies reported that cognitive decline occurs
in SHRSP (Kimura et al., 2000; Tang et al., 2015), thus we
believe future behavioral pharmacological evaluations of this
model will be useful. Equally important, changes in cortisol
metabolism in the brain were not measured in this study. In
addition, there were no changes in the expression of genes
relating to the renin-angiotensin-aldosterone system. Further
studies on MKP are needed to better understand the mechanisms
of tissue protection of neurons and blood vessels, and the
regulation of corticoids.
CONCLUSION
The present study was the first to examine the effects
on blood pressure and brain tissue by MKP in a severe
hypertension model. Intake of MKP-containing casein
hydrolysate CH-3 improved the survival rate of hypertensive
rats. Although there was no significant difference in blood
pressure, MKP suppressed symptoms of tissue damage in
hypertensive models, such as cerebral hemorrhage, astrogliosis,
and atrophy in the diencephalon region. In addition, gene
expression analysis suggested that MKP administration improved
cerebral circulation insufficiency and reduced oxidative stress.
Furthermore, corticoid regulation by MKP may be involved
in reducing damage in the brain. Our findings support the
use of MKP as an intervention to protect the brain during
hypertension, thereby contributing to the prevention of
cerebrovascular disease.
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